Search results
Results from the WOW.Com Content Network
Also, most synthetic cannabinoids are agonists of both cannabinoid receptors, CB 1 and CB 2, like THC; however, they often have greater binding affinity and therefore greater potency than THC, as seen in table two. Due to the greater potency, the standard doses of many synthetic cannabinoids may be less than 1 mg. [50]
Arachidonyl-2'-chloroethylamide (ACEA) is a synthetic agonist of the CB 1 (CB1R). ACEA is considered to be a selective cannabinoid agonist as it binds primarily to the CB1R and has low affinity to the CB 2 (CB2R) (K i = 1.4 nM for CB1R; K i = 3100 nM for CB2R). [1]
5F-CUMYL-PINACA (also known as SGT-25 and sometimes sold in e-cigarette form as C-Liquid) [1] is an indazole-3-carboxamide based synthetic cannabinoid. [2] 5F-CUMYL-PINACA acts as a potent agonist for the cannabinoid receptors, with the original patent claiming approximately 4x selectivity for CB 1, having an EC 50 of <0.1 nM for human CB 1 receptors and 0.37 nM for human CB 2 receptors. [3]
Another name for JWH-018, it is a full agonist at both cannabinoid receptors with some selectivity for CB 2. AM-679: 13.5: 49.5: 6.04: An iodobenzoylindole which acts as a moderately potent agonist for both cannabinoid receptors. AM-694: 0.08: 1.44: CB 1 (18×) 5.54: An iodobenzoylindole which acts as a potent and selective agonist for the CB 1 ...
WIN 55,212-2 is a potent cannabinoid receptor agonist [6] that has been found to be a potent analgesic [7] in a rat model of neuropathic pain. [8] It activates p42 and p44 MAP kinase via receptor-mediated signaling. [9] At 5 μM WIN 55,212-2 inhibits ATP production in sperm in a CB 1 receptor-dependent fashion. [10]
ADB-5'Br-PINACA (5'-Br-ADB-PINACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug.It was first identified in Abu Dhabi in September 2022 [1] but has subsequently been found in the US and Europe. [2]
ADB-5'Br-BUTINACA (ADB-B-5Br-INACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist which has been sold as a designer drug, [1] first detected in Philadelphia in the US in May 2022, [2] and subsequently found in South Korea, [3] Portugal and Sweden. [4]
Hexahydrocannabiphorol (HHCP, sometimes mistakenly referred to as hexahydroxycannabiphorol) is a semi-synthetic cannabinoid derivative which has been marketed since around 2021. [1] [2] It is believed to be made from the hydrogenation of tetrahydrocannabiphorol (THCP). THCP is only reported as a trace component of cannabis in 2019. [3]